Markets:

Overview

News

Currencies

International

Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

16.01 +1.61 (+11.18%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Tuesday's after hours session: top gainers and losers ↗

Today 17:00 EST

Via Chartmill

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗

November 06, 2025

Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028.

Via Chartmill

Topics Earnings

Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 16, 2025

Via Benzinga

Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket ↗

September 16, 2025

Via Benzinga

Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗

September 15, 2025

Via Stocktwits

Monte Rosa Therapeutics: Q4 Earnings Insights ↗

March 14, 2024

Via Benzinga

Here are the top movers in Monday's session. ↗

September 15, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 15, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

September 15, 2025

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗

September 15, 2025

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.

Via Benzinga

Monday's session: gap up and gap down stocks ↗

September 15, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

September 15, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 15, 2025

Via Benzinga

Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗

August 07, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected ↗

August 07, 2025

Monte Rosa Therapeutics (GLUE) reported Q2 2025 earnings with revenue beating estimates at $23.2M and a narrower EPS loss of -$0.15. Shares dipped pre-market despite strong results, as investors await...

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders ↗

March 20, 2025

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗

October 28, 2024

The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 28, 2024

Via Benzinga

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

October 28, 2024

Via Benzinga

Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗

October 28, 2024

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 28, 2024

Via Benzinga

GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 15, 2024

Via Benzinga

GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 26, 2024

Via Benzinga

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 26, 2024

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81...

Via Benzinga

GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 ↗

March 14, 2024

GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.